Pfizer Halts Development of Danuglipron

Pfizer has halted development of its anti-obesity drug Danuglipron, bloomberg.com reported. The decision follows reports of serious liver-related side effects in one clinical trial participant.

This move deals a blow to Pfizer’s efforts to compete with industry leaders Novo Nordisk and Eli Lilly in the booming weight-loss drug market. The company will not proceed with final-stage trials and will shift focus to early-stage obesity treatments.

According to Bloomberg, Pfizer saw weight loss drugs as a priority following its COVID-19 vaccine success. The market is projected to grow to $130 billion by 2030. Read 'Zamin' on Telegram!